This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Monoacyl lipopeptide agonist of toll-like receptor 2 (TLR2) as a vaccine adjuvant	A lipopeptide agonist of TLR2 could boost the efficacy of vaccines against infectious diseases. Chemical synthesis, SAR and *in vitro* testing of monoacyl lipopeptides identified a water soluble, nanomolar agonist of TLR2. In rabbits immunized with a vaccine based on the lactalbumin-α (Lalba) antigen or a diphtheria toxin antigen, coimmunization with the lead compound increased antigen-specific IgG levels in serum compared with coimmunization using vehicle. Next steps include testing the lead compound as an adjuvant to influenza vaccines in animals.	Patented; available for licensing	Salunke, D.B. *et al. J. Med. Chem.*; published online June 24, 2013; doi:10.1021/jm400620g **Contact:** Sunil A. David, The University of Kansas, Lawrence, Kan. e-mail: sdavid@ku.edu

SciBX 6(29); doi:10.1038/scibx.2013.773
Published online Aug. 1, 2013